Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 10/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.41 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103924 | 0.88 | SLC6A9 (0.49) | SLC6A9CACNA1ACACNA2D1CACNB1CACNA1C | |
| SCHEMBL4106918 | 0.87 | TP53 (0.44) | SLC6A9 | |
| SCHEMBL4097078 | 0.87 | TP53 (0.44) | SLC6A9 | |
| SCHEMBL18263843 | 0.83 | SLC6A9 (0.66) | SLC6A9OPRL1CACNA1ACACNA2D1CACNB1 | |
| SCHEMBL18263722 | 0.83 | SLC6A9 (0.66) | SLC6A9OPRL1CACNA1ACACNA2D1CACNB1 | |
| SCHEMBL18263721 | 0.83 | SLC6A9 (0.66) | SLC6A9OPRL1CACNA1ACACNA2D1CACNB1 | |
| SCHEMBL4102727 | 0.81 | SLC6A9 (0.36) | SLC6A9 | |
| SCHEMBL4088265 | 0.81 | SLC6A9 (0.36) | SLC6A9 | |
| SCHEMBL4093117 | 0.80 | SLC6A9 (0.48) | SLC6A9CACNA1ACACNA2D1CACNB1CACNA1C | |
| SCHEMBL4092989 | 0.80 | SLC6A9 (0.48) | SLC6A9CACNA1ACACNA2D1CACNB1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | SLC6A9 4784/4885OPRL1 3352/4885CACNA1A 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.